Dr Luan Linden Phillips PhD, MSc, BSc (Hons)

Institute of Applied Health Research
Honorary Research Fellow

Contact details

Department of Public Health, Epidemiology & Biostatistics
Institute of Applied Health Research
University of Birmingham
B15 2TT

Luan Linden-Phillips is a honorary Honorary Research Fellow in the Institute of Applied Health Research.  Luan was previously a senior analyst at the NIHR Horizon Scanning Research & Intelligence Centre (HSRIC), which provided information about selected new and emerging technologies to NICE, the Department of Health and national policy makers.

As well as managing the drug topic selection process, Luan leads external engagement with the pharmaceutical industry and other horizon scanning organisations across the UK, including NICE, the Medicines and Prescribing Centre, NHS England, UKMi, Scottish Medicines Consortium and the All Wales Medicines Strategy Group. Luan is also Co-chair of the User Group committee for UK PharmaScan, a joint Department of Health and ABPI project that provides an essential tool for the managed entry of medicines into the NHS. As part of her external engagement role, Luan has represented the Centre at NICE conferences, led on the delivery of UK PharmaScan Masterclasses for Industry delegates and has been responsible for advancing interdepartmental collaboration at the University of Birmingham, where the Centre is based.

Luan is an experienced analyst with a broad knowledge of the policy and market access issues that confront innovative new health technologies. She has previously held other, senior positions at the Centre, including specific work on devices and diagnostics. Working with stakeholders, including health professionals and commercial developers, Luan has produced and supervised a diverse range of tailored disease and technology-specific reports to assist in NHS policy and commissioning decisions. 

In 2014 she completed a PhD on the diffusion of pharmaceutical innovations, which involved accessing and engaging with senior pharmaceutical industry personnel.


  • PhD, Diffusion of Pharmaceutical Innovations, University of Birmingham, 2014
  • MSc in Toxicology, University of Birmingham, 2000
  • BSc (Hons) in Biosciences (Microbiology), University of Birmingham, 1999


Luan qualified with a first class degree in microbiology in 1999, followed by a Masters degree in toxicology from the University of Birmingham in 2000. She continued to specialise in this field, spending two years as a poisons specialist at the National Poisons Information Service, before joining the Horizon Scanning Centre in 2002. 

During her time at the NIHR HSRIC, Luan has worked across all areas of the Centre’s remit holding senior positions in all sub-teams including Drugs, MedTech and Research and Reviews. This has provided the basis for a unique knowledge of the Centre’s work in its entirety. Luan also recently completed a PhD alongside her horizon scanning roles, researching influences on pharmaceutical diffusion. 

Luan has produced many reports covering a diverse selection of health technologies, disease areas, patient groups and settings and has participated in conferences and panel sessions discussing the challenges affecting the use of new health technologies, which she was able to explore further through her PhD. 

As part of a wider university role, Luan teaches public health and epidemiology to medical students at undergraduate and graduate entry level, and is involved in training other health professionals in the methods of horizon scanning.



Diffusion and uptake of new health technologies; influence of the pharmaceutical industry in drug diffusion; early awareness and alert activities; health services research. 


Luan’s area of research includes the adoption and diffusion of new innovative health technologies. In addition to having published and presented on the subject, she has also completed a PhD on diffusion of innovations, specifically researching the area of pharmaceutical diffusion. 

PhD title: Pharmaceutical industry perspectives on factors that influence the adoption and diffusion of drugs in the UK: Four case studies 

Outline: A predominantly qualitative project utilising in depth interviews with senior pharmaceutical marketing personnel across multiple case studies to explore industry opinions on adoption influences that affect the uptake of new drugs in the UK.


Linden-Phillips L, Bitner-Glindzicz M, Lench N, Steel KP, Dawson S, Davis A, Simpson S, Packer C. The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss. International Journal of Audiology 2012; 1-10.

Tayo A, Ellis, J, Linden-Phillips L, Simpson S, Ward DJ. Emerging point of care tests for influenza: Innovation or Status quo. Influenza and Other Respiratory Viruses 2011; 6 (4) 291-298.

Plüddemann A, Heneghan C, Thompson M, Roberts N, Summerton N, Price C, Linden-Phillips L, Packer C. Prioritisation criteria for the selection of new diagnostic technologies for evaluation. BMC Health Services Research 2010; 10:109. 

Linden L, Vondeling H, Packer C, Cook A. Does NICE only appraise new pharmaceuticals? International Journal of Technology Assessment in Health Care 2007; 23(3): 349-353.

Gao L, Linden L, Parsons NJ, Cole JA, Smith H. Uptake of metabolites by gonococci grown with a lactate in a medium containing glucose: evidence for a surface location of the sialyltransferase. Microbial Pathogenesis 2000; 28 (5); 257-266